| 赵成燕,刘德亮,任洁雅,龙敏聪,郑嵘炅,鲁晓擘.基于TGF-β1/Smads信号通路探讨扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化的疗效机制[J].,2023,(13):2479-2482 |
| 基于TGF-β1/Smads信号通路探讨扶正化瘀胶囊联合恩替卡韦分散片治疗慢性乙型肝炎肝纤维化的疗效机制 |
| Based on TGF-β1/Smads Signal Pathway to Explore the Therapeutic Mechanism of Fuzheng Huayu Capsule Combined with Entecavir Dispersible Tablet in the Treatment of Chronic Hepatitis B Liver Fibrosis |
| 投稿时间：2023-02-09 修订日期：2023-02-28 |
| DOI：10.13241/j.cnki.pmb.2023.13.015 |
| 中文关键词: 扶正化瘀胶囊 恩替卡韦分散片 慢性乙型肝炎肝纤维化 TGF-β1/Smads信号通路 |
| 英文关键词: Fuzheng Huayu capsule Entecavir dispersible tablet Chronic hepatitis B liver fibrosis TGF-β1/Smads signaling pathway |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2017D01C17） |
|
| 摘要点击次数: 334 |
| 全文下载次数: 212 |
| 中文摘要: |
| 摘要 目的：基于转化生长因子-β1（TGF-β1）/Smads信号通路探讨恩替卡韦分散片联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的疗效机制。方法：纳入新疆医科大学第一附属医院2020年4月~2022年1月期间收治的慢性乙型肝炎肝纤维化患者104例，将患者根据随机数字表法分为对照组和观察组，例数各为52例。在常规治疗的基础上，对照组接受恩替卡韦分散片治疗，观察组接受扶正化瘀胶囊联合恩替卡韦分散片治疗。对比两组肝功能指标、肝纤维化指标、TGF-β1/Smads信号通路相关指标和影像学指标变化情况。结果：治疗24周后，两组丙氨酸氨基转移酶 （ALT）、天门冬氨酸氨基转移酶（AST）水平均下降，且观察组的下降程度较对照组更大（P<0.05）。治疗24周后，两组Ⅲ型前胶原（PCⅢ）、层粘连蛋白（LN）、Ⅳ型胶原（Ⅳ-C）、透明质酸（HA）水平均下降，且观察组的下降程度较对照组更大（P<0.05）。治疗24周后，两组TGF-β1mRNA、Smad2mRNA、Smad3mRNA水平下降， Smad7mRNA水平升高，且观察组的改善程度较对照组更大（P<0.05）。治疗24周后，两组门静脉内径、脾脏厚度均下降，且观察组较对照组更低（P<0.05）。结论：恩替卡韦分散片联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化，可改善肝功能，对肝纤维化具有明显的抑制作用，可能与调控TGF-β1/Smads信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: Based on transforming growth factor-β1 (TGF-β1) /Smads signaling pathway to explore the therapeutic mechanism of entecavir dispersible tabletcombined with Fuzheng Huayu capsule in the treatment of chronic hepatitis B liver fibrosis. Methods: 104 patients with chronic hepatitis B liver fibrosis who were admitted to The First Affiliated Hospital of Xinjiang Medical University from April 2020 to January 2022 were enrolled. The patients were divided into control group and observation group according to random number table method, with 52 cases in each group. On the basis of conventional treatment, the control group was treated with Entecavir dispersive tablet, and the observation group was treated with Fuzheng Huayu capsule combined with Entecavir dispersive tablet. The changes of liver function indexes, liver fibrosis indexes, TGF-β1/Smads signaling pathway related indexes and imaging indexes were compared between the two groups. Results: 24 weeks after treatment, the levels of alanine aminotransferase (ALT) and aspartate aminotransferase(AST) in the two groups decreased, and the decrease in the observation group was greater than that in the control group (P<0.05). 24 weeks after treatment, the levels of type Ⅲ procollagen (PC Ⅲ), laminin (LN), type Ⅳ collagen (Ⅳ-C) and hyaluronic acid (HA) in the two groups decreased, and the decrease in the observation group was greater than that in the control group (P<0.05). 24 weeks after treatment, the levels of TGF-β1mRNA, Smad2mRNA and Smad3mRNA in the two groups decreased, while the level of Smad7mRNA increased, and the improvement in the observation group was greater than that in the control group (P<0.05). 24 weeks after treatment, the diameter of portal vein and the thickness of spleen in the two groups decreased, and the observation group was lower than the control group(P<0.05). Conclusion: Entecavir dispersible tablet combined with Fuzheng Huayu capsule in the treatment of patients with chronic hepatitis B liver fibrosis can improve liver function and inhibit liver fibrosis, which may be related to the regulation of TGF-β1/Smads signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
